{
    "pmcid": "11133524",
    "summary": "The paper \"Prospects for the computational humanization of antibodies and nanobodies\" explores the challenges and advancements in the humanization of antibodies and nanobodies, with a focus on computational strategies. The goal of humanization is to reduce the immunogenicity of therapeutic antibodies by increasing their similarity to human antibodies, thereby minimizing the risk of anti-drug antibodies (ADAs) that can reduce drug efficacy.\n\n### Key Insights on SARS-CoV-2 Spike Protein and Nanobody Design:\n\n1. **Nanobodies and SARS-CoV-2:**\n   - Nanobodies, derived from camelids, are emerging as promising therapeutic agents due to their small size, which enhances expression, tumor penetration, and solubility while maintaining high binding affinity.\n   - The SARS-CoV-2 spike protein is a critical target for therapeutic nanobodies, as it plays a key role in viral entry into host cells.\n\n2. **Humanization Challenges:**\n   - Nanobodies have distinct structural features compared to conventional antibodies, making the direct application of antibody-focused humanization tools challenging.\n   - Humanization of nanobodies involves considerations such as maintaining hallmark residues in the FR2 region, which contribute to solubility and binding affinity. These residues are hydrophilic in nanobodies but hydrophobic in conventional antibodies.\n\n3. **Computational Humanization Tools:**\n   - The development of computational tools tailored for nanobodies is essential due to their unique structural characteristics.\n   - Llamanade is one of the first computational tools for nanobody humanization, focusing on maintaining key physicochemical properties while increasing humanness.\n   - AbNatiV, a deep-learning-based pipeline, quantifies the similarity of sequences to human VH or camelid VHH domains, balancing nativeness and humanness.\n\n4. **Validation and Optimization:**\n   - Computational humanization methods are validated through humanness scoring and binding affinity assessments. However, these methods face challenges due to limited nanobody data.\n   - The Llamanade pipeline demonstrated increased humanness scores and retained binding capabilities for SARS-CoV-2 binders, suggesting its potential for therapeutic development.\n\n5. **Multi-Parameter Optimization:**\n   - Humanization must be considered alongside other drug-like properties such as stability, solubility, and aggregation propensity.\n   - Machine learning approaches are being explored to co-optimize these properties, leveraging large datasets and high-throughput data for model training.\n\n6. **Future Directions:**\n   - There is a need for more robust validation methods and comprehensive datasets to improve the reliability of computational humanization tools.\n   - The development of nanobody-specific humanization tools is crucial, given their increasing application in therapeutics, including SARS-CoV-2.\n\nOverall, the paper emphasizes the importance of computational strategies in the humanization of nanobodies, particularly for targeting the SARS-CoV-2 spike protein. It highlights the need for tailored approaches that consider the unique structural features of nanobodies and the integration of multi-parameter optimization to enhance therapeutic efficacy and safety.",
    "title": "Prospects for the computational humanization of antibodies and nanobodies"
}